CF PharmTech Inc
02652
Company Profile
Business description
CF PharmTech Inc is focused on the R&D, manufacturing and commercialization of inhalation technologies and inhalation drugs, with a focus on treating respiratory diseases. It has developed a product portfolio with a broad coverage of patients, medical specialties, and therapeutic areas. Its products strategically benchmark global blockbuster drugs, covering four of the top ten inhalation drugs. Its first-approved product CF017, a budesonide suspension for inhalation targeting bronchial asthma, marked its first approved product.
Contact
No. 16, Hucundang Road
Xiangcheng Economic Development District
Jiangsu
Suzhou
CHNT: +86 51286867555
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
605
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks
Moated AI-proof tech play hiding in the ASX 100
ChatGPT and large language models should be a tailwind for this company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,972.70 | 2.50 | 0.03% |
| CAC 40 | 8,157.82 | 69.50 | -0.84% |
| DAX 40 | 24,128.98 | 26.47 | -0.11% |
| Dow JONES (US) | 49,230.71 | 79.61 | -0.16% |
| FTSE 100 | 10,379.08 | 77.93 | -0.75% |
| HKSE | 25,978.07 | 62.87 | 0.24% |
| NASDAQ | 24,836.60 | 398.10 | 1.63% |
| Nikkei 225 | 60,135.99 | 419.81 | 0.70% |
| NZX 50 Index | 12,874.94 | 9.99 | -0.08% |
| S&P 500 | 7,165.08 | 56.68 | 0.80% |
| S&P/ASX 200 | 8,747.90 | 1.30 | -0.01% |
| SSE Composite Index | 4,079.87 | 0.03 | -0.00% |